Analysis of hepatitis B surface antigen (HBsAg) using high‐sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Hepatology Research

• Publication date

  2017-09-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/hepr.12979PMID 28884879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody

  2017cited by this paper
• Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application

  2017cited by this paper
• Novel monitoring of hepatitis B reactivation based on ultra‐high sensitive hepatitis B surface antigen assay

  2017cited by this paper
• Chronic hepatitis B surface antigen seroclearance‐related immune factors

  2017cited by this paper
• Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long‐term follow‐up study

  2016cited by this paper
• Innate immune targets of hepatitis B virus infection.

  2016cited by this paper
• Viral life cycle of hepatitis B virus: Host factors and druggable targets

  2016cited by this paper
• American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

  2015cited by this paper
• Effect of serum hepatitis B surface antigen levels on predicting the clinical outcomes of chronic hepatitis B infection: A meta‐analysis

  2015cited by this paper
• American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

  2015cited by this paper
• Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B

  2014cited by this paper
• Innate immune responses in hepatitis B virus (HBV) infection

  2014cited by this paper
• Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up

  2014cited by this paper
• JSH Guidelines for the Management of Hepatitis B Virus Infection

  2014cited by this paper
• Application of a Newly Developed High-Sensitivity HBsAg Chemiluminescent Enzyme Immunoassay for Hepatitis B Patients with HBsAg Seroclearance

  2013cited by this paper
• Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study

  2013cited by this paper
• Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis.

  2013cited by this paper
• Dysfunctional B‐cell activation in cirrhosis resulting from hepatitis C infection associated with disappearance of CD27‐Positive B‐cell population

  2012cited by this paper
• Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

  2012cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B.

  2011cited by this paper
• Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

  2010cited by this paper
• Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.

  2010cited by this paper
• Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy

  2010cited by this paper
• Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes.

  2010cited by this paper
• Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside‐naïve HBeAg‐positive patients with chronic hepatitis B *

  2010cited by this paper
• Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg‐negative patients

  2010cited by this paper
• Increased immunoglobulin A in alcoholic liver cirrhosis: exploring the response of B cells to Toll‐like receptor 9 activation

  2009cited by this paper
• Predictors of Treatment Response in Chronic Hepatitis B

  2009cited by this paper
• Hepatitis B virus infection.

  2008cited by this paper
• Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.

  2008cited by this paper
• Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers.

  2007cited by this paper
• Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BLai C-L, for the BEHoLD AI463027 Study Group (Queen Mary Hosp, Hong Kong; et al) N Engl J Med 354:1011–1020, 2006§

  2007cited by this paper
• Long-Term Presence of HBV in the Sera of Chronic Hepatitis B Patients with HBsAg Seroclearance

  2007cited by this paper
• Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance.

  2007cited by this paper
• The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

  2006cited by this paper
• Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

  2006cited by this paper
• Coexistence of Hepatitis B Surface Antigen (HBs Ag) and Anti-HBs Antibodies in Chronic Hepatitis B Virus Carriers: Influence of “a” Determinant Variants

  2006cited by this paper
• Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.

  2006cited by this paper
• Prevention of mortality from hepatitis B and hepatitis C.

  2006cited by this paper
• Noninvasive Assessment of Liver Fibrosis by Measurement of Stiffness in Patients With Chronic Hepatitis C

  2006cited by this paper
• Hepatitis B Virus DNA-negative Dane Particles Lack Core Protein but Contain a 22-kDa Precore Protein without C-terminal Arginine-rich Domain*

  2005cited by this paper
• Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C

  2005cited by this paper
• Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance.

  2005cited by this paper
• Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin.

  2004cited by this paper
• Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay.

  2004cited by this paper
• Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients

  2004cited by this paper
• Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

  2004cited by this paper
• Hepatitis B virus infection--natural history and clinical consequences.

  2004cited by this paper
• Determination of hepatitis B virus subtypes by an enzyme immunoassay method using monoclonal antibodies to type‐specific epitopes of HBsAg

  2001cited by this paper
• A dominant hepatitis B virus population defective in virus secretion because of several S‐gene mutations from a patient with fulminant hepatitis

  2001cited by this paper
• Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg.

  1997cited by this paper
• Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B.

  1996cited by this paper
• The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes

  1995cited by this paper
• Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen

  1994cited by this paper
• Impaired Function of Macrophage Fcγ Receptors and Bacterial Infection in Alcoholic Cirrhosis

  1994cited by this paper
• Enhancement of HBsAg detection in serum of patients with chronic liver disease following removal of circulating immune complexes.

  1994cited by this paper
• Impaired function of macrophage Fc gamma receptors and bacterial infection in alcoholic cirrhosis.

  1994cited by this paper
• Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B

  1993cited by this paper
• Two distinct types of hepatitis in experimental hepatitis B virus infection.

  1980cited by this paper
• DNA of a Human Hepatitis B Virus Candidate

  1974cited by this paper
• European Association for the Study of the Liver

  1971cited by this paper

• Comparative performance of the Siemens Atellica and Abbott Architect assays for HBsAg quantification in patients with chronic hepatitis B or hepatitis Delta.

  2026cites this paper
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• A novel monoclonal antibody targeting a conserved inner region of the hepatitis B virus envelope enables broad detection of immune escape variants

  2025cites this paper
• Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC

  2024cites this paper
• An overview of occult hepatitis B infection (OBI) with emphasis on HBV vaccination

  2024cites this paper
• Does the ultrasensitive HBsAg Next assay enhance Hepatitis B diagnosis? An evaluation of analytical performances.

  2024cites this paper
• Optical nanomaterial-based detection of biomarkers in liquid biopsy

  2024cites this paper
• Biomarkers of transfusion transmitted occult hepatitis B virus infection: Where are we and what next?

  2024cites this paper
• PREVALENCE OF OCCULT HEPATITIS B INFECTION AMONG BLOOD DONORS IN SAINT PETERSBURG

  2023cites this paper
• Occult Hepatitis B Virus Infection: An Update

  2022cites this paper
• An Ideal Hallmark Closest to Complete Cure of Chronic Hepatitis B Patients: High-sensitivity Quantitative HBsAg Loss

  2022cites this paper
• A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook

  2022cites this paper
• HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure

  2022cites this paper
• Is Cure of Hepatitis B Infection a Mission Possible?

  2021cites this paper
• The positive rates of hepatitis B surface antibody in youth after booster vaccination: a 4-year follow-up study with large sample

  2021cites this paper
• Controversies in Treating Chronic Hepatitis B Virus Infection: Discordant Serologic Results.

  2021cites this paper
• Occult Hepatitis B Infection

  2021cites this paper
• How to determine whether functional hepatitis B cure is achieved?

  2020cites this paper
• Chemiluminescent Optical Fiber Immunosensor Combining Surface Modification and Signal Amplification for Ultrasensitive Determination of Hepatitis B Antigen

  2020cites this paper
• Hepatitis B virus persistence and reactivation

  2020cites this paper
• The contribution of more sensitive hepatitis B surface antigen assays to detecting and monitoring hepatitis B infection.

  2020cites this paper
• HBS Ag seroclearance and seroconversion time in Patients with chronic hepatitis B Infection

  2020cites this paper
• Prevalence of occult HBV infection in Western countries

  2020cites this paper
• Current Knowledge of Occult Hepatitis B Infection and Clinical Implications

  2019cites this paper
• Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B

  2019cites this paper
• Non-invasive biomarkers for chronic hepatitis B virus infection management.

  2019cites this paper
• Evaluation of in vitro screening and diagnostic kits for hepatitis B virus infection.

  2019cites this paper
• Update of the statements on biology and clinical impact of occult hepatitis b virus infection.

  2019cites this paper
• Evaluation of in vitro screening and diagnostic kits for hepatitis C virus infection.

  2018cites this paper